Skip to content

Autonomic Recalibration

Autonomic Recalibration Approach to Myofascial Pain Elimination

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06603168
Acronym
ART
Enrollment
20
Registered
2024-09-19
Start date
2023-04-27
Completion date
2024-02-27
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autonomic Dysregulation, Chronic Pain (Back / Neck)

Keywords

chronic pain, autonomic nervous system, sympathetic dominance, myofascial pain, Sympathetic tone, dysfunctional pain, Primal Reflex Release Technique, shear wave elastography, heart rate variability, galvanic skin response, Rokoko, motion capture, range of motion, posture

Brief summary

The goal of this clinical trial is to learn if Autonomic Recalibration works to reduce sympathetic dominance to alleviate dysfunctional myofascial pain. The main questions it aims to answer are: How is the Autonomic Nervous System (ANS) affected during Autonomic Recalibration Treatment (ART)? How are myofascial tissue properties impacted from ART? Participants will: Have 2 treatments of ART on consecutive days. Wear sensors to track HRV (heart rate variability) and GSR to verify autonomic recalibration. Measure changes in range of motion by wearing a Rokoko motion capture suit. Measure changes in muscle stiffness through shear wave elastography.

Detailed description

Myofascial pain contributes to opioid misuse and opioid use disorder. Alternative non-drug therapies for myofascial pain, such as osteopathic manipulative treatment, are critical areas of research. An unexplored approach in osteopathic manipulative treatment is recruiting the regulatory assistance of the autonomic nervous system (ANS) to alleviate myofascial pain. Autonomic Recalibration Technique (ART) is a manual and behavioral approach that employs osteopathic principles in addressing the neurobiological mechanisms that regulate myofascial pain. Our central hypothesis is that ART utilizes ANS regulation to restore myofascial function and alleviate chronic myofascial pain. The scientific premise of this proposal is the need to document mechanistic evidence that the ANS can be recruited to alleviate and eliminate pain by employing osteopathic principles. While elements of this approach have been employed by various practitioners, including manual and integrative clinicians including osteopaths, the innovation is to combine a manual bottom-up approach to shut down sympathetic tone, and a top-down approach to address trauma-based triggers that propagate pain. If successful, these preclinical data will be used in future grants to propose a clinical trial of ART as an additional technique in osteopathic manipulative treatment to provide an alternative to surgical or drug treatment of chronic myofascial pain.

Interventions

OTHERAutonomic Recalibration Treatment

An initial history to r/o pathology and document a chief complaint relevant to pain is conducted. An initial head to toe assessment of withdrawal or startle reflex behavior in response to palpation is performed to identify trigger points and establish patterns of sympathetic dominance throughout the myofascial system. The pattern of sympathetic dominance (pattern of trigger point) is addressed during treatment by Primal Reflex Release Technique Protocol to inhibit somatic afferent feedback loops and rebalance the autonomic nervous system towards a state of parasympathetic dominance. The absence of a trigger point indicates that the treatment is complete.

Sponsors

Edward Via Virginia College of Osteopathic Medicine
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This pilot study design is a pretest-posttest cohort study.

Eligibility

Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* dysfunctional myofascial pain, i.e., ongoing pain not relevant to an acute perturbation (e.g., recent injury) or known underlying condition (e.g., cancer).

Exclusion criteria

* known skin allergies to gel as found in common cosmetic or household products * can't make treatment appointments on two consecutive days * myofascial pain is deemed functional (normal response to acute injury or ongoing pathology) * lacking a COVID-19 vaccination and a booster shot.

Design outcomes

Primary

MeasureTime frameDescription
Pain Intensity (NRS Pain Scale)Pre/Post for each day of treatment. 2 days total.0-10 Pain Rating. 0=no pain to 10=pain as intense as you can imagine
Heart Rate VariabilityPre/Post for each day of treatment. 2 days total.Changes in HRV (ms) pre/post and Day 1/Day 2.
Galvanic Skin Response (GSR)Pre/Post for each day of treatment. 2 days total.Comparison of GSR peak counts pre/post and Day 1/Day 2.
Muscle Stiffness using Shear Wave ElastographyPre/Post for each day of treatment. 2 days total.Changes in muscle stiffness (kPa) measured by Ultrasound.
Nociceptive Trigger PointsPre/Middle/Post for each day of treatment. 2 days total.Log of reported trigger points during nociceptive start exam. Taken Pre, Middle, and Post ART on Day 1 and Day 2.
Changes in mobilityPre/Post for each day of treatment. 2 days total.Posture/mobility changes using multivariate morphometric analysis.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026